Vanda Pharmaceuticals Announces Presentation Of VEC-162 Phas

Vanda Pharmaceuticals Inc. (Nasdaq: VNDA), a biopharmaceutical company focused on the development and commercialization of clinical-stage product candidates for central nervous system disorders, today announced that Phase II data for its sleep disorder compound VEC-162 will be presented at the SLEEP 2006 20th Anniversary Meeting of the Associated Professional Sleep Societies at the Salt Palace Convention Center in Salt Lake City on June 22nd.

The oral presentation, titled "The Melatonin Agonist VEC-162 Immediately Phase-Advances the Human Circadian System" will take place on June 22, 2006 in Room 250ABC at 9:15 a.m. MDT. The data from the study will be presented by Dr. Shantha M.W. Rajaratnam, Division of Sleep Medicine, Brigham and Women's Hospital, Harvard Medical School.

NOTE REGARDING FORWARD-LOOKING STATEMENTS

The oral presentation referred to in this release will contain forward- looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, including statements regarding Vanda's plans for VEC-162 and its other product candidates. Words such as, but not limited to, "believe," "expect," "anticipate," "estimate," "intend," "plan," "targets," "likely," "will," "would," and "could," and similar expressions or words, will identify such forward-looking statements. Such forward-looking statements will be based upon expectations at the time of the presentation that involve risks, changes in circumstances, assumptions and uncertainties. Important factors that could cause actual results to differ materially from those reflected in Vanda's forward-looking statements may include, among others, a failure of VEC-162 or Vanda's other product candidates to be demonstrably safe and effective, a failure to obtain regulatory approval for VEC-162 or Vanda's other product candidates or to comply with ongoing regulatory requirements, a lack of acceptance of VEC-162 or Vanda's other product candidates in the marketplace, or a failure to become or remain profitable, Vanda's inability to obtain the capital necessary to fund its research and development activities, a loss of any of the company's key scientists or management personnel, and other factors that are described in the "Risk Factors" section of Vanda's report on Form 10-Q for the fiscal quarter ended March 31, 2006. No forward-looking statements can be guaranteed and actual results may differ materially from such statements. The information in the oral presentation will be provided only as of the date of the presentation, and Vanda undertakes no obligation to update any forward- looking statements contained in such presentation on account of new information, future events, or otherwise, except as required by law.

ABOUT VANDA PHARMACEUTICALS INC.:

Vanda Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of clinical-stage product candidates for central nervous system disorders. The Company has three product candidates in clinical development. Vanda's lead product candidate, iloperidone, is a compound for the treatment of schizophrenia and bipolar disorder and is in a Phase III clinical trial for schizophrenia. Vanda's second product candidate, VEC-162, is a compound for the treatment of insomnia and depression which is currently in a Phase III clinical trial for insomnia. Vanda's third product candidate, VSF-173, is a compound for the treatment of excessive sleepiness and is ready for a Phase II clinical trial. For more on Vanda Pharmaceuticals Inc., please visit http://www.vandapharma.com.

Vanda Pharmaceuticals Inc.
http://www.vandapharma.com
(责任编辑：泉水)

搜索

热门标签:

Vanda Pharmaceuticals Announces Presentation Of VEC-162 Phas